ORCHARD THERAPEUTICS PLC-ADR (ORTX)
US68570P2002 - ADR
Overall ORTX gets a fundamental rating of 3 out of 10. We evaluated ORTX against 588 industry peers in the Biotechnology industry. ORTX may be in some trouble as it scores bad on both profitability and health. ORTX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ORTX has reported negative net income.
In the past year ORTX has reported a negative cash flow from operations.
ORTX had negative earnings in each of the past 5 years.
In the past 5 years ORTX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ORTX (-36.05%) is better than 64.76% of its industry peers.
With a Return On Equity value of -90.81%, ORTX perfoms like the industry average, outperforming 44.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| ROIC | N/A |
ROA(3y)-55.93%
ROA(5y)-54.34%
ROE(3y)-102.43%
ROE(5y)-87.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 69.19%, ORTX belongs to the best of the industry, outperforming 82.97% of the companies in the same industry.
In the last couple of years the Gross Margin of ORTX has remained more or less at the same level.
ORTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ORTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ORTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORTX has been increased compared to 5 years ago.
The debt/assets ratio for ORTX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -5.75, we must say that ORTX is in the distress zone and has some risk of bankruptcy.
ORTX's Altman-Z score of -5.75 is on the low side compared to the rest of the industry. ORTX is outperformed by 69.31% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that ORTX is not too dependend on debt financing.
ORTX has a Debt to Equity ratio of 0.20. This is in the lower half of the industry: ORTX underperforms 69.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.75 |
ROIC/WACCN/A
WACC8.34%
2.3 Liquidity
A Current Ratio of 3.12 indicates that ORTX has no problem at all paying its short term obligations.
The Current ratio of ORTX (3.12) is worse than 67.62% of its industry peers.
ORTX has a Quick Ratio of 2.98. This indicates that ORTX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.98, ORTX is not doing good in the industry: 67.96% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 71.01% over the past year.
Looking at the last year, ORTX shows a very strong growth in Revenue. The Revenue has grown by 35.23%.
Measured over the past years, ORTX shows a very strong growth in Revenue. The Revenue has been growing by 108.22% on average per year.
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q59.46%
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5YN/A
Revenue growth Q2Q9%
3.2 Future
ORTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.90% yearly.
Based on estimates for the next years, ORTX will show a very strong growth in Revenue. The Revenue will grow by 54.70% on average per year.
EPS Next Y74.37%
EPS Next 2Y32.68%
EPS Next 3Y25.41%
EPS Next 5Y14.9%
Revenue Next Year24%
Revenue Next 2Y58.1%
Revenue Next 3Y63.4%
Revenue Next 5Y54.7%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ORTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ORTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ORTX's earnings are expected to grow with 25.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.68%
EPS Next 3Y25.41%
5. Dividend
5.1 Amount
ORTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORCHARD THERAPEUTICS PLC-ADR
NASDAQ:ORTX (1/23/2024, 7:00:02 PM)
16.7
+0.05 (+0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap380.11M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.05% | ||
| ROE | -90.81% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.19% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)71.01%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y74.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)35.23%
Revenue growth 3Y108.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y